Stock CLDX CELLDEX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Celldex Therapeutics, Inc.

Equities

CLDX

US15117B2025

Real-time Estimate Cboe BZX
Other stock markets
 12:40:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
37.2 USD -2.36% Intraday chart for Celldex Therapeutics, Inc. -6.75% -6.09%
May. 15 Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study MT
May. 15 Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study
Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Celldex Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Celldex Therapeutics Proposes $250 Million Underwritten Common Stock Offering
Sector Update: Health Care Stocks Weaker Monday Afternoon
Celldex Therapeutics Shares Rise After Q4 Revenue Tops Estimates
Sector Update: Health Care Stocks Mixed Premarket Monday
Celldex Therapeutics Q4 Loss Widens, Revenue Rises; Shares Up Pre-Bell
Celldex Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Celldex Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Celldex Therapeutics Prices $200.5 Million Share Offering
Celldex Shares Rise as Phase 2 Trial Shows Barzolvolimab Meets Primary Efficacy Endpoint for Chronic Spontaneous Urticaria
Sector Update: Health Care Stocks Advance Premarket Monday
Traders Await Next Catalyst as US Equity Futures Edge Higher Pre-Bell
Sector Update: Health Care
Rate Cut Hopes Push Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday
Top Premarket Gainers
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
Celldex Therapeutics Says Prurigo Nodularis Phase 1b Study of Barzolvolimab Showed 'Durable Reductions in Itch'
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLDX Stock
  4. News Celldex Therapeutics, Inc.
  5. Other languages